Results 141 to 150 of about 391,360 (247)

Using root cause analysis to improve the quality of loaner instrument receiving in the central sterile supply department: A retrospective study. [PDF]

J Int Med Res
Qin N, Huang H, Chen H, Rao J, Zhou X, Zeng A, Zeng Q.   +6 more
europepmc   +1 more source

Integrating the root cause analysis to machine learning interpretation for predicting future failure. [PDF]

Heliyon, 2023
Aditiyawarman T, Soedarsono JW, Setiawan Kaban AP, Suryadi, Rahmadani H, Riastuti R.   +5 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Root Cause Analysis of Omissions and Delays in the Initiation of Neoadjuvant Chemotherapy in Eligible Patients with Breast Cancer in British Columbia, Canada. [PDF]

Curr Oncol
Chan JLH, Lee JJ, Ohm H, Isaac KV, Nichol A.   +4 more
europepmc   +1 more source

Monitoring and Root Cause Analysis of Clinical Biochemistry Turnaround Time at a Tertiary Care Institute. [PDF]

Cureus, 2023
Prasad P, Kumar R, Kumar S, Sinha P.
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Insights from a measles outbreak root cause analysis in Ethiopia - 2024. [PDF]

Pan Afr Med J
Alemu MA, Dema ST, Anteneh HA, Guade HT, Gebrekidan AH, Mersha AM, Lakew GA, Tufa YA, Shibeshi EZ, Nibzane GT, Hailemariam FT, Kita YG, Yimam F, Ayana WB, Hailekiros T, Amene K, Atakilti R, Alemu E, Yeshaw O, Malumo S, Kokebe MA, Getaneh MW, Afele MA, Masresha BG.   +23 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Root causes and fields of action to address unplanned hospitalisation in long-term care: a multiple case study with root-cause analysis. [PDF]

BMC Nurs
Pohontsch NJ, Huckle TA, Jarchow AM, Balzer K, Silies KT.   +4 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source